Tilatamig

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

Approval Year

Substance Class	Protein Created by `admin` on `Wed Apr 02 14:03:19 GMT 2025` Edited by `admin` on `Wed Apr 02 14:03:19 GMT 2025`
Protein Type	BISPECIFIC ANTIBODY
Protein Sub Type	IGG1\|LAMDA\|KAPPA
Sequence Origin	HUMAN
Sequence Type	COMPLETE
Record UNII	Y5RC3BF6LQ
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

Tilatamig

Official Name

English

Immunoglobulin G1 [133-cysteine,227-valine,241-phenylalanine,242-glutamic acid,338-serine,361-cysteine,373-tryptophan], anti-(human epidermal growth factor receptor) (human monoclonal RAA22 ?1-chain), (133?126??)-disulfide with [126-cysteine,216-valine]

Preferred Name

English

immunoglobulin G1-kappa/G1-lambda, anti-[Homo sapiens MET (met proto-oncogene, hepatocyte growth factor (HGF) receptor, HGFR, scatter factor (SF) receptor, HGF/SF receptor, receptor tyrosine-protein kinase c-met, papillary renal cell carcinoma 2, RCCP2)]

Common Name

English

tilatamig [INN]

Common Name

English

TILATAMIG [USAN]

Common Name

English

Code System Code Type Description

NCI_THESAURUS

C207004

Created by admin on Wed Apr 02 14:03:19 GMT 2025 , Edited by admin on Wed Apr 02 14:03:19 GMT 2025

PRIMARY

INN

13020

Created by admin on Wed Apr 02 14:03:19 GMT 2025 , Edited by admin on Wed Apr 02 14:03:19 GMT 2025

PRIMARY

USAN

NO-13

Created by admin on Wed Apr 02 14:03:19 GMT 2025 , Edited by admin on Wed Apr 02 14:03:19 GMT 2025

PRIMARY

FDA UNII

Y5RC3BF6LQ

Created by admin on Wed Apr 02 14:03:19 GMT 2025 , Edited by admin on Wed Apr 02 14:03:19 GMT 2025

PRIMARY

CAS

2868265-50-1

Created by admin on Wed Apr 02 14:03:19 GMT 2025 , Edited by admin on Wed Apr 02 14:03:19 GMT 2025

PRIMARY

SMS_ID

300000048254

Created by admin on Wed Apr 02 14:03:19 GMT 2025 , Edited by admin on Wed Apr 02 14:03:19 GMT 2025

PRIMARY

From	To
2_199	4_214
4_134	4_194
4_23	4_88
3_139	3_198
3_22	3_90
2_366	2_424
2_260	2_320
2_143	2_219
2_22	2_96
1_361	2_348
1_374	1_432
1_268	1_328
1_236	2_228
1_233	2_225
1_151	1_207
1_133	3_126
1_22	1_96

Glycosylation Type

MAMMALIAN

Glycosylation Link Type	Site
N	1_304
N	2_296

Related Record Type Details


					RO03J093CP

EPIDERMAL GROWTH FACTOR RECEPTOR

TARGET->LIGAND

Amount:


					QA085PMU8Q

HEPATOCYTE GROWTH FACTOR RECEPTOR

TARGET->LIGAND

Amount:

Related Record Type Details


					Y5RC3BF6LQ

Tilatamig

ACTIVE MOIETY

Amount:

Structural Modifications

Modification Type	Location Site	Location Type	Residue Modified	Extent	Fragment Name	Fragment Approval
AMINO_ACID_SUBSTITUTION	[1_1] [2_1]	N-TERMINUS			PIDOLIC ACID	SZB83O1W42
AMINO ACID REMOVAL	[1_454] [2_446]	C-TERMINUS			LYSINE	K3Z4F929H6

Name	Property Type	Amount	Referenced Substance	Defining	Parameters	References
MOL_WEIGHT:NUMBER(CALCULATED)	CHEMICAL
Molecular Formula	CHEMICAL